Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vericel Corporation

Latest From Vericel Corporation

Bristol Opts In On Second Neuro Candidate Under Prothena Alliance

Neither the mechanism nor indication is disclosed, but BMS is paying $80m up front for global rights to PRX019, which one analyst speculated might be an Alzheimer’s candidate.

Deals Business Strategies

Amphastar Plans To Launch Second OTC Product Also In Emergency Medicine Category

Amphastar plans in 2024 to submit application to FDA to move its Rextovy 4mg naloxone hydrochloride intranasal formulation from Rx to OTC. Advertising to drive Primatene Mist awareness planned.

OTC Drugs Prescription To OTC Switch

Merck & Co. To Enter Ophthalmology With EyeBio Buyout

Veteran developers stay on to accelerate development of potential first-in-class drug to challenge Bayer/Regeneron’s Eylea and Roche’s Vabysmo in a deal worth up to $3bn.

Clinical Trials Commercial

Stock Watch: All Bayer’s Roads Lead To Unpalatable

Investors reacted quite differently to Bayer’s first-quarter results and those of its licensing partner Regeneron. There are sound reasons for this. It seems unlikely that one will help the other.

Stock Watch Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Aastrom Biosciences, Inc.
    • Genzyme Biosurgery